Treatment Services

Treatment Services Fucaso

Patient Story

Thai Patient New Zealand Patient

Patient Support

CAR-T Therapy Center Multiple Myeloma Specialist Team Insurance Introduction

About Car-T Therapy

What is Car-T? Who is Car-T for? For Caregivers Car-T therapy vs. conventional therapy Find CAR T Medical Center Cart-T Drugs for Multiple Myeloma Car-T Treatment Process Guide CAR-T Post-Treatment Care and Rehabilitation Guide

About Multiple Myeloma

What can I do after my myeloma is confirmed? Multiple Myeloma Treatment Options What is Mutiple Myeloma?

Counseling for Help

Resources

Blogs Downloads

Email Email business@cartservice.org WhatsApp WhatsApp +44 7714904040
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found
fucaso fucaso Learn More

We use cookies to ensure that you get the best experience on our website. Clicking "Accept Cookies" means you agree with our Privacy Policy.

Accept Cookies